You need to enable JavaScript in order to use the AI chatbot tool powered by ChatBot


Primary Human Hepatocytes in Drug Development: Challenges and Opportunities Part 1

Donald Tweedie, PhD, and Edward LeCluyse, PhD, share lessons learned over a combined 70 years in drug development and research on alternative drug metabolism and toxicological methods. Dr. Tweedie is recently retired from Merck after a 30-year career in drug discovery and development. Previously, he held positions at Pfizer, Bristol-Myers Squibb, and Boehringer Ingelheim. Dr. LeCluyse is the Chief Scientist in the LifeSciences Division at LifeNet Health and a faculty member at The University of North Carolina at Chapel Hill.

Topics include:

  • The importance of using primary human hepatocytes that retain their native in vivo functions
  • How incorporating non-parenchymal cells in hepatocyte cultures creates a more in vivo-like liver environment
  • The investigative correlation between healthy and diseased liver cells and their incorporation into models for research